logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Indications
    3. Bilateral Tonicclonic Seizure With Generalized Onset

    Medications for Bilateral Tonicclonic Seizure With Generalized Onset

    FiltersReset Filters
    32 results

    • fycompa

      (perampanel)
      Eisai Inc.
      Usage: FYCOMPA is indicated for the treatment of partial-onset seizures in patients aged 4 and older, and as adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 12 and older with epilepsy.

    • keppra

      (levetiracetam)
      UCB, Inc.
      Usage: KEPPRA is indicated for treating partial-onset seizures in patients aged 1 month and older. It is also approved as adjunctive therapy for myoclonic seizures in patients 12 years and older with juvenile myoclonic epilepsy and for primary generalized tonic-clonic seizures in patients 6 years and older with idiopathic generalized epilepsy.

    • lacosamide

      (Lacosamide)
      Zydus Pharmaceuticals USA Inc.
      Usage: Lacosamide is indicated for the treatment of partial-onset seizures and as adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 4 years and older.

    • lacosamide

      (lacosamide)
      Sintetica US LLC
      Usage: Lacosamide Injection is indicated for the treatment of partial-onset seizures and as adjunctive therapy for primary generalized tonic-clonic seizures in patients aged 4 years and older.

    • lacosamide

      (Lacosamide)
      Zydus Pharmaceuticals USA Inc.
      Usage: Lacosamide is indicated for treating partial-onset seizures in patients aged 4 and older and as adjunctive therapy for primary generalized tonic-clonic seizures in the same age group.

    • lamotrigine

      (lamotrigine extended-release)
      Yiling Pharmaceutical, Inc.
      Usage: Lamotrigine Extended-Release Tablets are indicated for adjunctive therapy in patients aged 13 and older with primary generalized tonic-clonic seizures and partial-onset seizures. They can also be used for conversion to monotherapy in individuals with partial-onset seizures on a single antiepileptic drug. Safety is not established in patients under 13.

    • lamotrigine

      (lamotrigine extended-release)
      Camber Pharmaceuticals Inc
      Usage: Lamotrigine Extended-Release Tablets are indicated as adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures in patients aged 13 and older. It is also indicated for conversion to monotherapy for partial-onset seizures in the same age group. Safety in patients under 13 has not been established.

    • lamotrigine

      (Lamotrigine)
      Aurobindo Pharma Limited
      Usage: Lamotrigine tablets for oral suspension are indicated as adjunctive therapy for partial-onset, primary generalized tonic-clonic, and Lennox-Gastaut seizures in patients aged 2 and older. They are also used for maintaining bipolar I disorder, delaying mood episode occurrences, but not for treating acute episodes.

    • lamotrigine

      (Lamotrigine)
      Taro Pharmaceuticals U.S.A., Inc.
      Usage: Lamotrigine is indicated as adjunctive therapy for partial-onset, primary generalized tonic-clonic, and Lennox-Gastaut syndrome seizures in patients aged 2 and older, and for conversion to monotherapy in adults with partial-onset seizures. It is also used for the maintenance treatment of bipolar I disorder to delay mood episodes.

    • lamotrigine

      (Lamotrigine)
      Northstar Rx LLC.
      Usage: Lamotrigine is indicated as adjunctive therapy for partial-onset seizures, primary generalized tonic-clonic seizures, and Lennox-Gastaut syndrome seizures in patients aged 2 and older. It is also used for the maintenance treatment of bipolar I disorder to delay mood episodes, but not for acute episodes.